Share on StockTwits

Enzymotec (NASDAQ:ENZY) will be posting its Q214 quarterly earnings results on Tuesday, August 5th. Analysts expect Enzymotec to post earnings of $0.10 per share and revenue of $14.88 million for the quarter. Enzymotec has set its FY14 guidance at $0.64-0.94 EPS.

Enzymotec (NASDAQ:ENZY) last released its earnings data on Wednesday, May 14th. The company reported $0.24 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.17 by $0.07. The company had revenue of $23.70 million for the quarter, compared to the consensus estimate of $19.40 million. Enzymotec’s revenue was up 29.0% compared to the same quarter last year. On average, analysts expect Enzymotec to post $0.82 EPS for the current fiscal year and $1.09 EPS for the next fiscal year.

Enzymotec (NASDAQ:ENZY) traded down 0.07% during mid-day trading on Monday, hitting $14.99. 6,645 shares of the company’s stock traded hands. Enzymotec has a 52 week low of $12.10 and a 52 week high of $35.12. The stock’s 50-day moving average is $14.25 and its 200-day moving average is $20.09. The company has a market cap of $322.2 million and a price-to-earnings ratio of 23.62.

Several analysts have recently commented on the stock. Analysts at Zacks upgraded shares of Enzymotec from an “underperform” rating to a “neutral” rating in a research note on Tuesday, July 15th. They now have a $15.20 price target on the stock. On a related note, analysts at Jefferies Group cut their price target on shares of Enzymotec from $25.00 to $14.50 in a research note on Monday, May 19th. They now have a “hold” rating on the stock. One research analyst has rated the stock with a sell rating, two have issued a hold rating and two have issued a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus price target of $19.93.

Enzymotec Ltd. is engaged in manufacturing of ingredients and medical foods company. Its technologies, research, and clinical validation process enables the Company to develop differentiated solutions across a variety of products.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.